Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients. Methods: This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively. Results: Among the 928 patients in this study, 82 were hepatitis B surface antigen (HBsAg)-positive (the CHB group) and 846 were HBsAg-negative (the non-CHB group). The median follow-up time was 50.5 months (interquartile range [IQR]=25.6–69.7 months). Multivariable analyses showed longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted hazard ratio [aHR]=0.49, 95% confidence interval [CI]=0.29–0.82, P=0.007) and after IPTW (aHR=0.42, 95% CI=0.26–0.70, P<0.001). The CHB group also had a longer OS than the non-CHB group both before IPTW (HR=0.55, 95% CI=0.33–0.92, log-rank P=0.02) and after IPTW (HR=0.53, 95% CI=0.32–0.99, log-rank P=0.02). Although liver-related deaths did not occur in the non-CHB group, two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively. Conclusions: Our findings indicate that HBV-associated DLBCL patients receiving antiviral treatment have significantly longer TTP and OS after R-CHOP treatment than HBV-unassociated DLBCL patients.
Abstract
Background/Aims: Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients. Methods: This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively. Results: Among the 928 patients in this study, 82 were hepatitis B surface antigen (HBsAg)-positive (the CHB group) and 846 were HBsAg-negative (the non-CHB group). The median follow-up time was 50.5 months (interquartile range [IQR]=25.6–69.7 months). Multivariable analyses showed longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted hazard ratio [aHR]=0.49, 95% confidence interval [CI]=0.29–0.82, P=0.007) and after IPTW (aHR=0.42, 95% CI=0.26–0.70, P<0.001). The CHB group also had a longer OS than the non-CHB group both before IPTW (HR=0.55, 95% CI=0.33–0.92, log-rank P=0.02) and after IPTW (HR=0.53, 95% CI=0.32–0.99, log-rank P=0.02). Although liver-related deaths did not occur in the non-CHB group, two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively. Conclusions: Our findings indicate that HBV-associated DLBCL patients receiving antiviral treatment have significantly longer TTP and OS after R-CHOP treatment than HBV-unassociated DLBCL patients.
참고문헌 (49)
- Bréchot C, "Pathogenesis of hepatitis B virus-related hepatocellular carcinoma : old and new paradigms", Gastroenterology, 127(5 Suppl 1), pp.S56~S61 (2004)
- Terry Cheuk-Fung Yip, "Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact", Clinical and Molecular Hepatology, 27(2), pp.273~277 (2021), 대한간학회[DOI]
- Joo Hyun Oh, "The latest global burden of liver cancer: A past and present threat", Clinical and Molecular Hepatology, 29(2), pp.355~357 (2023), 대한간학회
- Chen DG, "Clinicopathological and prognostic features of hepatitis B virusassociated diffuse large B-cell lymphoma : a single-center retrospective study in China", Infect Agent Cancer, 16, pp.57~ (2021)
- Wei Z, "HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era : result from a multicenter retrospective analysisin China", Med Oncol, 31, pp.845~ (2014)
- Engels EA, "Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea : a cohort study", Lancet Oncol, 11, pp.827~834 (2010)
- Chen J, "Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin’slymphoma after chemotherapy", PLoS One, 8, pp.e69400~ (2013)
- Lee DH, "Association of chronic hepatitis B infection and antiviral treatment with the development of the extrahepatic malignancies : A nationwide cohortstudy", J Clin Oncol, 40, pp.3394~3405 (2022)
- Moon Haeng Hur, "The imitator of immune-tolerant chronic hepatitis B: A killer in disguise", Clinical and Molecular Hepatology, 29(2), pp.363~366 (2023), 대한간학회
- Cerhan JR, "Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma : the InterLymph Non-Hodgkin Lymphoma Subtypes Project", J Natl Cancer Inst Monogr, 2014, pp.15~25 (2014)
- Nogai H, "Pathogenesis of non-Hodgkin’slymphoma", J Clin Oncol, 29, pp.1803~1811 (2011)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2008), IARC Lyon
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy : a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
- Hyung Joon Yim, "Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop", Clinical and Molecular Hepatology, 26(4), pp.411~429 (2020), 대한간학회[DOI]
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Lister TA, "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease : Cotswolds meeting", J Clin Oncol, 7, pp.1630~1636 (1989)
- Armitage JO, "Staging non-Hodgkin lymphoma", CA Cancer J Clin, 55, pp.368~376 (2005)
- Eichstaedt KE, "A less conservative method to adjust for familywise error rate in neuropsychological research : the Holm’s sequential Bonferroni procedure", NeuroRehabilitation, 32, pp.693~696 (2013)
- Austin PC, "Variance estimation when using inverse probability of treatment weighting(IPTW)with survival analysis", Stat Med, 35, pp.5642~5655 (2016)
- Wang R, "Statistics in medicine--reporting of subgroup analyses in clinical trials", N Engl J Med, 357, pp.2189~2194 (2007)
- Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
- Deng L, "Hepatitis B virus-associated diffuse large B-cell lymphoma : unique clinical features, poor outcome, and hepatitis B surface antigendriven origin", Oncotarget, 6, pp.25061~25073 (2015)
- Janahi EM, "The inhibition of hepatitis B virus by APOBEC cytidine deaminases", J Viral Hepat, 20, pp.821~828 (2013)
- Zhang Y, "Roles of APOBEC3 in hepatitis B virus(HBV)infection and hepatocarcinogenesis", Bioengineered, 12, pp.2074~2086 (2021)
- Rebhandl S, "AID", APOBEC deaminases and cancer, 2015, pp.2, 320~333
- Siriwardena SU, "Functions and malfunctions of mammalian DNA-Cytosine deaminases", Chem Rev, 116, pp.12688~12710 (2016)
- Henrik Zhang, "Approaches to quantifying hepatitis B virus covalently closed circular DNA", Clinical and Molecular Hepatology, 28(2), pp.135~149 (2022), 대한간학회[DOI]
- Luo X, "Association of hepatitis B virus covalently closed circular DNA and human APOBEC3B in hepatitis B virus-related hepatocellular carcinoma", PLoS One, 11, pp.e0157708~ (2016)
- Koning FA, "Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets", J Virol, 83, pp.9474~9485 (2009)
- Jais JP, "The expression of 16 genesrelated to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab", Leukemia, 22, pp.1917~1924 (2008)
- Lai CL, "Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B", J Hepatol, 66, pp.275~281 (2017)
- van der Molen RG, "Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B", Hepatology, 40, pp.738~746 (2004)
- Hiam-Galvez KJ, "Systemic immunity in cancer", Nat Rev Cancer, 21, pp.345~359 (2021)
- Tjwa ET, "Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virusinfection", J Virol, 86, pp.4102~4109 (2012)
- Nam JY, "Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B", J Viral Hepat, 25, pp.552~560 (2018)
- Albillos A, "Cirrhosis-associated immune dysfunction : distinctive features and clinical relevance", J Hepatol, 61, pp.1385~1396 (2014)
- Ren W, "Genetic landscape of hepatitis B virus-associated diffuse large Bcell lymphoma", Blood, 131, pp.2670~2681 (2018)
- Murata K, "Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues : a new potential target for HBV infection", Gut, 67, pp.362~371 (2018)
- Lasfar A, "Interferon lambda : Toward a dual role in cancer", J Interferon Cytokine Res, 39, pp.22~29 (2019)
- Stiff A, "Investigations of interferon-lambda for the treatment of cancer", J Innate Immun, 7, pp.243~250 (2015)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Fontana RJ, "Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives", Gastroenterology, 146, pp.914~928 (2014)
- Tajiri K, "A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab", Case Rep Gastroenterol, 7, pp.195~201 (2013)